About: Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency
Creator	Haskologlu, Sule Ikinciogullari, Aydan Kendirli, Tanil Ceylaner, Serdar Sevinc, Selin Aytekin, \| Bal, Kostel Candan Islamoglu, \| Figen Dogu, \| Guner, \| Keles, \| Sevgi, \|
Source	Medline; PMC
abstract	Biallelic mutations in the dedicator of cytokinesis 8 gene (DOCK8) cause a progressive combined immunodeficiency (CID) characterized by susceptibility to severe viral skin infections, atopic diseases, recurrent respiratory infections, and malignancy. Hematopoietic stem cell transplantation (HSCT) is only curative treatment for the disease. However, there is limited information about long‐term outcome of HSCT and its effect to protect against cancer development in DOCK8‐deficient patients. In this study, we retrospectively evaluated clinical and immunologic characteristics of 20 DOCK8‐deficient patients and outcome of 11 patients who underwent HSCT. We aimed to report the experience of our center and the result of the largest transplantation series of DOCK8 deficiency in our country. Median follow‐up time is 71 months (min‐max: 16‐172) in all patients and 48 months (min‐max: 5‐84) in transplanted patients. Atopic dermatitis (18/20), recurrent respiratory tract infections (17/20), and food allergy (14/20) were the most frequent clinical manifestations. Failure to thrive (13/20), liver problems (12/20), bronchiectasis (11/20), chronic diarrhea (10/21), and autism spectrum disorders (3/20) were remarkable findings in our series. Elevated IgE level (20/20) and eosinophilia (17/20), low IgM level (15/20), and decreased CD3+ T (10/20) and CD4+ T (11/20) cell count were prominent laboratory findings. HSCT was performed in 11 patients. All patients achieved adequate engraftment and showed improvement in their clinical and immunologic findings. Atopic dermatitis and food allergies improved in all patients, and their dietary restriction was stopped except one patient who was transplanted recently. The frequency of infections was decreased. The overall survival is 91% in HSCT‐received patients and 80% in all. HSCT at the earliest possible period with most suitable donor‐ and patient‐specific appropriate conditioning regimen and GvHD prophylaxis is lifesaving for DOCK8 deficiency cases.
has issue date	2020-03-11(xsd:dateTime)
bibo:doi	10.1111/pai.13236
bibo:pmid	32108967
has license	no-cc
sha1sum (hex)	30497f23bbf41b8312b258cf2de9018213326d48
schema:url	https://doi.org/10.1111/pai.13236
resource representing a document's title	Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency
has PubMed Central identifier	PMC7228270
has PubMed identifier	32108967
schema:publication	Pediatr Allergy Immunol
resource representing a document's body	covid:30497f23bbf41b8312b258cf2de9018213326d48#body_text
is schema:about of	named entity 'Hematopoietic stem cell transplantation (HSCT)' named entity 'immunodeficiency' named entity 'disease' named entity 'cite' named entity 'Clinical' named entity 'LONG-TERM OUTCOME' named entity 'SUSCEPTIBILITY' named entity 'LIMITED' named entity 'PROGRESSIVE' named entity 'INFORMATION' named entity 'ARTICLE' named entity 'VIRAL' named entity 'MUTATIONS' named entity 'HEMATOPOIETIC STEM CELL TRANSPLANTATION' named entity 'How' named entity 'Kostel' named entity 'features' named entity 'Hematopoietic stem cell transplantation' named entity 'HSCT' named entity 'HSCT' named entity 'DOCK8' named entity 'HSCT' named entity 'treosulfan' named entity 'malignancy' named entity 'dendritic cell' named entity 'antimicrobial' named entity 'failure to thrive' named entity 'IgE' named entity 'consanguinity' named entity 'Allergy' named entity 'Miami' named entity 'cholestatic' named entity 'prophylaxis' named entity 'HSCT' named entity 'DOCK8 deficiency' named entity 'flow cytometry' named entity 'immunological' named entity 'severe infections' named entity 'HSCT' named entity 'central nervous' named entity '3/20' named entity 'Ankara University' named entity 'food allergies' named entity 'chimerism' named entity 'DOCK8' named entity 'DOCK8' named entity 'MTX' named entity 'organ damage' named entity 'thymic' named entity 'transfusion' named entity 'tacrolimus' named entity 'herpes infection' named entity 'NHL' named entity 'DOCK8' named entity 'stem cells' named entity 'GvHD' named entity 'CD3+' named entity 'HSCT' named entity 'atopy' named entity 'follow-up' named entity 'antiviral' named entity 'DOCK8' named entity 'phenotype' named entity 'phenotype' named entity 'Antithymocyte globulin' named entity 'flow cytometry' named entity 'interferon' named entity 'protein' named entity 'HSCT' named entity 'DOCK8 deficiency'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software